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Abstract 
Background: Penicillin is important for treatment of pigs, but data on its absorption and disposition in pigs are 
sparse. This is reflected by the variation in recommended dosages in the literature. Inadequate dosage may lead to 
treatment failure and selection of resistant bacteria. To optimize treatment regimens, plasma exposure to benzylpeni-
cillin for two sustained release formulations of procaine benzylpenicillin for intramuscular administration was studied 
in growing pigs by means of tandem mass spectrometry (UPLC–MS/MS). One formulation was an aqueous suspen-
sion, Ethacilin® vet (ETH), and the other an oily suspension, Ultrapen vet (UPA). Benzylpenicillin exposure after intrave-
nous administration of potassium benzylpenicillin was also explored. Exposure profiles were first studied after single 
administrations of the approved dosages in healthy pigs and then after repeated administration of different dosages 
in pigs inoculated intranasally with an Actinobacillus pleuropneumoniae serotype 2 strain.
Results: After intravenous administration of benzylpenicillin (n = 6), maximum plasma concentration (Cmax), 1860–
9318 µg/L, was observed after 15 min. At four h, plasma concentrations decreased to 15–76 µg/L. After intramuscular 
administration of ETH (n = 6) Cmax, 1000–4270 µg/L, was observed within one h (tmax) in 5 pigs but at four h in one 
pig. Cmax for UPA (n = 6), 910–3220 µg/L, was observed within one h in three pigs, but at four or 24 h in three pigs. For 
both ETH and UPA, the terminal phase was characterized by slow decline compared with intravenous administration. 
Repeated administration of different dosages of ETH and UPA in pigs inoculated with A. pleuropneumoniae (n = 54) 
showed that the approved dose for UPA (30 mg/kg, qd) but not for ETH (20 mg/kg, qd) gave adequate plasma expo-
sure for bacteria with a penicillin MIC of 500 µg/L. However, more frequent dosing of ETH (bid) or increased dosage 
gave an adequate exposure.
Conclusions: The approved dosage of ETH provided insufficient plasma exposure for adequate therapy of infections 
caused by A. pleuropneumoniae or other bacteria with a penicillin MIC of 500 µg/L. More frequent ETH dosing (bid) or 
an increased dosage would improve exposure. The approved dosage of UPA however provided adequate exposure.
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Background
Emergence of antibiotic resistance is driven by the selec-
tion pressure exerted by the use of antibiotics. To tackle 
the increasing burden of resistance, the development of 
new drugs is crucial [1] and this is also highlighted in the 
European plan to tackle antibiotic resistance [2]. How-
ever, it is recognized that incentives for developing new 
classes of antibiotics are weak [3]. It is therefore essen-
tial to preserve the efficacy of antibiotics already on the 
market for as long as possible, not the least in veterinary 
medicine [4, 5]. Prudent and rational use of antibiotics 
is therefore important not only for the veterinary sec-
tor but also in the holistic perspective of “One health” 
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[6]. Prudent use and surveillance to counteract spread of 
resistant bacteria have made it possible to maintain ben-
zylpenicillin as a first line antibiotic for treatment of the 
most common infections in production animals such as 
pigs, cattle and sheep in Sweden [7]. Benzylpenicillin for 
injection also dominates overall use for pigs in Sweden 
[8, 9]. Thus, the use of broad-spectrum drugs has largely 
been avoided in contrast to the situation in many other 
countries as can be appreciated from data on sales of 
antibiotics for animals in Europe [10].
Penicillin is a narrow-spectrum antibiotic that was dis-
covered in the late 1920s and has been used in animals 
for several decades. Although benzylpenicillin dominates 
antibiotic use for pigs in Sweden, data on basic pharma-
cokinetic and pharmacodynamic properties (PK/PD) of 
penicillin in pigs are sparse and emanate from studies 
performed in healthy animals [11–13]. This is reflected 
by the variation in recommended dosages in the litera-
ture [11–13]. In pigs, mainly slow-release preparations 
of procaine benzylpenicillin are used for intramuscu-
lar injections. The prolonged absorption phase from the 
injection site of such formulations extends the plasma 
exposure and consequently the dosing interval. Oil-based 
formulations of procaine benzylpenicillin are considered 
to prolong absorption time even further [14].
The antibacterial effect of benzylpenicillin is time 
dependent and the therapeutic response depends on the 
time within a dosing interval that the free drug concen-
tration exceeds the minimum inhibitory concentration 
(MIC) of the infecting bacteria [15]. Thus, to ensure treat-
ment efficacy, knowledge of the relation between plasma 
exposure and the MIC of pathogenic bacteria is required 
[5]. For bacteria such as Actinobacillus pleuropneumo-
niae, which may cause severe respiratory disease in pigs, 
a majority of the wild type isolates have benzylpenicillin 
MICs of 250 or 500  µg/L [9, 16]. However, the plasma 
protein binding of benzylpenicillin in pigs is around 45% 
[17, 18] and to ensure clinical efficacy, the total drug con-
centration should therefore exceed about 1000 µg/L.
Conclusively, the sparse information on benzylpenicil-
lin exposure after administration of different formula-
tions in pigs warrants further studies of this antibiotic. 
The objective of this study was therefore to investigate 
the penicillin exposure in both healthy and experimen-
tally infected growing pigs after administration of ben-
zylpenicillin products available on the Swedish market.
Methods
Animals
This study was approved by the regional ethical com-
mittee in Uppsala (License C 37/16) and by the Swedish 
Medical Products Agency (License no. 5.1-2016-16737). 
All pigs used in the study originated from one specific 
pathogen-free (SPF) herd [19]. The pigs were either pure-
bred Yorkshire or two- or three-breed hybrids of York-
shire, Landrace, Hampshire or Duroc. All pigs were 11 to 
13 weeks old and weighed between 34 and 49 kg at the 
beginning of the three trials. None of the pigs received 
any medication other than the investigated benzylpeni-
cillin formulations preceding or during the trial period.
Part I of the study was conducted as two sub-sets of tri-
als involving nine pigs in their home environment in each 
trial set. In total, 18 pigs, nine gilts and nine barrows, 
originating from six litters were used. Each experimen-
tal group was balanced for sex and litter of origin. The 
pigs were kept in their original pens together with their 
siblings during sampling. The pigs were weighed the day 
before the trials were conducted.
In Part II of the study, 24 pigs from six litters were used. 
In Part III, 30 pigs from another six litters were used. In 
parts II and III, all pigs were transported to the National 
Veterinary Institute (NVI). On arrival, pigs were weighed 
and marked for identification. Pigs were allocated to one 
of four (Part II) or five (Part III) groups with six pigs in 
each group. The groups were balanced for sex, weight on 
arrival and litter of origin. Each group was housed in sep-
arate rooms with separate ventilation and manure clear-
ing systems previously described in detail [20].
After acclimatization for one  week, all pigs in Part 
II and III were inoculated intranasally with  1011 col-
ony forming units of A. pleuropneumoniae serotype 2 
(strain 700/89, NVI) grown overnight on Bacto PPLO 
(pleuropneumoniae-like organism) agar at 37°C in a 
humid atmosphere with 5%  CO2 and harvested into 0.9% 
NaCl. Pigs were monitored closely after inoculation and 
observed for the appearance of respiratory signs. Treat-
ments were initiated when pigs showed signs consistent 
with an A. pleuropneumoniae infection (fever, coughing, 
increased breathing rate, loss of appetite).
Dosage regimens
Three different benzylpenicillin formulations were used 
to study the exposure profiles in healthy pigs and pigs 
inoculated intranasally with A. pleuropneumoniae sero-
type 2. The three formulations used were: Bensylpeni-
cillin Meda (BPM) containing 148.4–158.1  mg/mL 
potassium benzylpenicillin (Meda AB, Solna, Sweden); 
Ethacilin vet (ETH) (Intervet AB, Sollentuna, Sweden) 
containing 300  mg/mL procaine benzylpenicillin in an 
aqueous suspension, and Ultrapen vet (UPA) (N-vet, 
Uppsala, Sweden), containing 300 mg/mL procaine ben-
zylpenicillin in an oily suspension. Dosage regimens for 
the three parts of the study are shown in Table 1.
Intravenous injections (IV) were administered in an 
ear vein and intramuscular injections (IM) in the lat-
eral neck. All syringes were weighed on a scale with an 
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accuracy of 0.01  g (Tamro Med-Lab AB, Hisings Kärra, 
Sweden) after they had been filled with the dose calcu-
lated and re-weighed after drug-administration to deter-
mine the administered amount of benzylpenicillin as 
exactly as possible.
Sample collection
In part I, blood samples (n = 9) were collected over 24 h 
from each pig. In pigs given 10  mg/kg BPM IV, ETH 
20  mg/kg IM or UPA 30  mg/kg IM, samples were col-
lected prior to administration (0  h) and at 15, 30, 60, 
90, 120, 240 (4 h), 720 (12 h) and 1440 (24 h) min after 
administration. In pigs given 20 mg/kg BPM IV, samples 
were collected prior to administration (0 h) and at 15, 30, 
60, 120, 240, 480 (8 h), 720 (12 h)  and 1440  (24 h) min 
after administration.
In Part II, blood samples were collected before the 
first administration (0 h) and at 1, 12 and 24 h after each 
administration from pigs treated once daily (qd). For pigs 
treated twice daily (bid), samples were collected before 
the first administration (0 h) and at 1 and 12 h after each 
treatment. The last sample in all pigs was collected 24 h 
after the last administration.
In part III, blood samples were collected before the first 
administration (0  h) and daily at 1, 12  h and 24  h after 
each administration. On day two, samples were not col-
lected 12 h after administration due to limitations in the 
number of samples allowed by the ethics’ consent. For 
the same reason, samples were not collected 1 h after the 
second administration on day two from pigs treated bid 
for 5 days. Moreover, for all pigs treated for 5 days, sam-
ples were not collected 1 and 12 h after each administra-
tion on day four due to the constraint on the number of 
sampling occasions allowed. The last sample in all pigs 
was collected 24 h after the last administration.
Pigs were restrained by the snout to allow for sampling. 
Blood samples were collected from the jugular vein in 
7  mL evacuated plastic tubes (BD  Vacutainer®, Stock-
holm, Sweden) containing ethylenediaminetetraacetic 
acid (EDTA) as additive. Samples were immediately after 
collection centrifuged for 10 min at 224 g (Hettich centri-
fuge, EBA 200, KRUUSE Svenska AB, Uppsala, Sweden) 
and the plasma transferred to plastic storage tubes (2 mL 
Screw Cap Micro Tubes, Sarstedt AB, Helsingborg, Swe-
den) and stored at − 20 °C for at most 48 h. The samples 
were then transferred to − 80 °C and stored until analysis.
Sample analysis
Liquid chromatography tandem mass spectrometry 
(UPLC–MS/MS) was used for the determination of 
total benzylpenicillin concentration in plasma. All sam-
ples were thawed to room temperature. 200  μL of Mil-
liQ-water and 100 μL of pig plasma were added to each 
micro tube. 50 μL of MilliQ-water/AcN (1:1) and 50 μL 
of internal standard solution (2.0 μg of benzylpenicillin-
d5 free acid/mL in MilliQ-water: acetonitrile (1:1) were 
added. The tubes were then Vortexed for 10  min (1650 
pulse) after which they were centrifuged at 11500g for 
Table 1 Dosing regimens for three benzylpenicillin formulations used to determine the exposure profiles in grower pigs
Table 1. Dosing regimens for three benzylpenicillin formulations used to determine the exposure profiles in healthy pigs and pigs inoculated intranasally with an 
Actinobacillus pleuropneumoniae serotype 2 strain. The three formulations used were: Ethacilin vet (ETH) (Intervet AB, Sollentuna, Sweden) containing 300 mg/
ml procaine benzylpenicillin in an aqueous suspension; Ultrapen vet (UPA) (N-vet, Uppsala, Sweden), containing 300 mg/ml procaine benzylpenicillin in an oily 
suspension, and Bensylpenicillin Meda (BPM) containing potassium benzylpenicillin (Meda AB, Solna, Sweden)
a Ethacilin vet 30 mg/kg was administered twelve h before first Ultrapen vet administration
*Not applicable
Study part n pigs Medicinal product Admin route Loading dose 
(mg/kg)
Maintenance 
dose (mg/kg)
Dosing interval Treatment 
duration 
(days)
I 3 Bensylpenicillin Meda IV – 10 Single dose Na*
I 3 Bensylpenicillin Meda IV – 20 Single dose Na*
I 6 Ethacilin vet IM – 20 Single dose Na*
I 6 Ultrapen vet IM – 30 Single dose Na*
II 6 Ethacilin vet IM – 20 Every 12 h 3
II 6 Ethacilin vet IM – 20 Every 24 h 3
II 6 Ethacilin vet IM – 30 Every 24 h 3
II 6 Ultrapen vet IM – 30 Every 24 h 3
III 6 Ethacilin vet IM – 30 Every 12 h 5
III 6 Ultrapen vet IM – 30 Every 24 h 5
III 6 Ultrapen vet IM – 30 Every 24 h 3
III 6 Ultrapen vet IM 60 30 Every 24 h 3
III 6 Ultrapen vet IM 30a 30 Every 24 h 3.5
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5 min. Then 100 μL of sample was transferred to a vial. 
400 μL MilliQ-water was added and vortexed for 1 min 
(1650 pulse). The sample was then injected into the 
UPLC-MS/MS system Quatro Ultima Pt. The ionization 
mode used was positive electrospray. The separation was 
performed with an analytical column: UPLC BEH C18, 
1.7 μm 2.1 × 100 mm at 60 °C. The chromatography was 
performed using a mobile phase consisting of a combina-
tion of 0.1% formic acid with water and 0.1% formic acid 
and acetonitrile in a gradient program with a flow-rate 
of 200 μL/min. Data acquisition was with Selected Reac-
tion Monitoring (SRM)/Multiple Reaction Monitoring 
(MRM): penicillin G: precursor m/z 335[M + H] + prod-
uct m/z 160, penicillin G-d5: precursor m/z 340[M + H]+ 
product m/z 160.
The quantification was carried out with calibration 
curves constructed by linear regression of the chroma-
tographic peak area ratio (analyte/internal standard) as 
a function of analyte concentration. The calibration sam-
ples were prepared by spiking blank plasma with known 
amounts of analyte standard. For evaluation of the accu-
racy, the quantification precision as percentage relative 
standard deviation (RSD) and the linearity of the method 
quality control (QC) samples in three different concen-
trations were prepared by spiking blank plasma. The 
standards and the QC samples were treated in the same 
way as the plasma samples obtained from the pigs.
The lower limit of quantification for benzylpenicillin 
was 10 µg/L in pig plasma and the standard curves were 
linear in the range 10–15,000 ng/mL of plasma. When a 
sample had a determined concentration of benzylpeni-
cillin above the highest calibration standard, the plasma 
sample was diluted in accordance to a standard operation 
procedure. The relative standard deviation (CV%) of the 
intra-assay variability for the quality controls used in the 
analysis of plasma samples containing 10, 30, 752, 7520 
and 13,700 ng/mL (n = 5 for each concentration) ranged 
between 0.6% and 9.9%.
Results
Single dose exposure to benzylpenicillin after IV and IM 
dosing to healthy pigs (Part I)
After IV administration of BPM 10 or 20 mg/kg, plasma 
concentrations decreased from 1860–9318 µg/L at 0.25 h 
to 15–76  µg/L at 4  h (2–3 orders of magnitude). Indi-
vidual plasma concentration time courses are shown in 
Fig.  1. In three of six pigs, a terminal phase with lower 
elimination rate was observed. After dose-normalization, 
plasma concentrations obtained after 20  mg/kg super-
imposed those obtained after 10 mg/kg. Benzylpenicillin 
plasma concentration was lower than the limit of quan-
tification (10 µg/L) twelve h after administration in four 
pigs and after 24 h in the remaining two pigs.
Following IM administration, total benzylpenicillin 
plasma concentrations varied between pigs for both for-
mulations as demonstrated in Fig.  1. After administra-
tion of 20 mg/kg ETH, maximum concentrations (Cmax) 
ranged from 1000 to 4270 µg/L and were observed within 
one h (tmax) in five pigs but was delayed until 4 h in one 
pig. After administration of 30 mg/kg UPA, Cmax varied 
between 910 and 3220 µg/L. In all pigs, a peak in concen-
tration was observed within one h after administration. In 
three of the pigs this was the Cmax, but in three pigs, there 
was a second peak at 4 or 24 h which was the Cmax. For 
both ETH and UPA the terminal phase was characterized 
by a slow decline compared with IV administration. For 
both formulations, the plasma concentration was above 
100 µg/L in all but one pig, 24 h post administration.
Exposure to benzylpenicillin after repeated IM dosing 
to pigs inoculated with A. pleuropneumoniae (Part II)
Concentration–time courses of benzylpenicillin in indi-
vidual pigs after repeated IM dosing of ETH 20  mg/kg 
qd and bid, ETH 30 mg/kg qd and UPA 30 mg/kg qd for 
three consecutive days are shown in Fig.  2. Aiming at 
maintaining a free benzylpenicillin plasma concentra-
tion above the MIC for wild type A. pleuropneumoniae 
of 500  µg/L (total concentration ≈ 1000  µg/L) for more 
than 50% of the dosing-interval, only ETH 20 mg/kg bid 
and UPA30 mg/kg qd, gave adequate exposures through 
the last dosing interval (Fig.  2). Administered as ETH 
20  mg/kg bid, the total plasma concentration over a 
dosing-interval was similar to UPA 30 mg/kg qd during 
the third (48–72 h) day of dosing (Fig. 2). However, there 
was more pronounced fluctuation with higher peaks and 
lower trough levels after the ETH bid than the UPA qd 
Fig. 1 Total plasma concentration–time courses of three 
benzylpenicillin formulations in healthy grower pigs. Total plasma 
concentration–time courses of benzylpenicillin in healthy pigs after 
intravenous administration of either 10 mg/kg (n = 3, solid blue 
lines) or 20 mg/kg (n = 3, dashed blue lines) and intramuscular 
administration of 20 mg/kg Ethacilin (n = 6, red solid lines) and 
30 mg/kg Ultrapen (n = 6, black solid lines). Each line represents an 
individual pig
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regimen. ETH 20 or 30 mg/kg qd did not give adequate 
exposure.
Exposure to benzylpenicillin after repeated IM dosing 
to pigs inoculated with A. pleuropneumonia (Part III)
Concentration–time courses of benzylpenicillin after 
repeated IM dosing of either ETH 30  mg/kg bid for 
5 days, UPA 30 mg/kg qd for 5 days, UPA 30 mg/kg qd 
for 5 days starting 12 h after a start-dose of ETH 30 mg/
kg and UPA 30 mg/kg qd for 5 days starting 24 h follow-
ing a start-dose of UPA 60  mg/kg are shown in Fig.  3. 
Total benzylpenicillin plasma concentrations were 
maintained above a MIC of 500  µg/L (total concentra-
tion ≈ 1000  µg/L) for all individual pigs and all dosage 
regimens. The variability within the studied population 
was similar to that observed in Part II and occurred in all 
groups studied. This variation appeared larger in animals 
treated with UPA compared to those treated with ETH. 
Concentration–time data from all pigs and all doses are 
provided in supplementary files (Additional file 1).
No adverse reactions following administrations of 
either of the benzylpenicillin products were observed.
Discussion
This study shows that the exposure to benzylpenicil-
lin after different dosage-regimens of two depot formu-
lations commonly used in clinical practice in growing 
pigs is highly variable, irrespective of dosage regimen. 
Both, the concentration–time  course between pigs and 
between dosing intervals in the same pig varied. The 
variability appeared more pronounced in pigs admin-
istered the oil suspension (UPA), compared to procaine 
benzylpenicillin administered as an aqueous suspension 
(ETH). A high variability in benzylpenicillin plasma con-
centration–time courses after IM administration is in 
agreement with other studies in pigs [11, 13]. The vari-
ability is likely mainly due to the absorption-phase of the 
benzylpenicillin disposition. However, repeated restrain-
ing contributes to a stressful sampling situation in pigs, 
and stress constitutes a potential source of variability 
in the pharmacokinetics of drugs [21]. In clinical set-
tings, pigs are not normally subjected to repeated sam-
pling. Hence, the variability in plasma exposure caused 
by stress would be expected to be less important under 
field conditions. The observed high variability will how-
ever remain a challenge for adequate dose selection in 
Fig. 2 Total plasma concentration–time courses of benzylpenicillin in pigs after repeated intramuscular dosing of different formulations. 
Total plasma concentration–time courses of benzylpenicillin after repeated intramuscular dosing of different formulations of the drug in pigs 
experimentally inoculated with Actinobacillus pleuropneumoniae serotype 2. Each line represents an individual pig. Plot a 20 mg/kg Ethacilin qd to 
six pigs for 3 days. Plot b 20 mg/kg Ethacilin bid to six pigs for 3 days. Plot c 30 mg/kg Ethacillin qd to six pigs for 3 days. Plot d 30 mg/kg Ultrapen 
qd to six pigs for 3 days. The horizontal lines denote the approximate total plasma concentration of benzylpenicillin necessary to exceed MIC of 
500 µg/L for A. pleuropneumoniae, considering a protein binding of 45%
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the treatment of bacterial infections in pigs with depot 
formulations of benzylpenicillin.
The apparently longer terminal half-life after IM 
administration compared with IV administration indi-
cates absorption rate limited kinetics (flip-flop) where 
the absorption from the administration site limits the 
rate of elimination. Double peaks observed in the plasma 
concentrations of benzylpenicillin in three pigs given 
the oil suspension (UPA) in Part I of the study, may also 
be explained by the extended absorption time from the 
depot formulation. In Parts II and III of the study there 
were also indications of erratic absorption and delayed 
 Cmax in some of the pigs given the oil suspension, 
although double peaks could not be identified due to less 
frequent sampling than in Part I. The phenomenon of 
double peaks has previously been reported by Apley and 
Thacker [11] for intramuscular as well as a needleless air-
injection system of 44  mg/kg procaine benzylpenicillin 
in pigs although information on the suspension medium 
was not provided. In the current study, the higher dose of 
the oil suspension, compared to the aqueous suspension, 
could be a reason for double peaks. However, double 
peaks were not observed in another study in pigs, in spite 
of even higher doses (100 mg/kg) of procaine penicillin G 
after intramuscular injections [13]. Nor was it possible to 
detect any double peaks after repeated administration of 
the aqueous suspension in this study. Thus, it seems more 
likely that the double peaks were a result of the formula-
tion in oil.
The antibacterial effect of β-lactam antibiotics is 
time-dependent [22]. This means that the time within a 
dose-interval that the drug exposure exceeds MIC of the 
target bacteria is decisive for treatment outcome. A clini-
cal point estimate is that the free concentration should 
exceed MIC of the target bacteria at least 50% of the 
dose-interval to ensure bactericidal effect [15, 23]. This 
could be desirable in acute infections caused by patho-
gens such as A. pleuropneumoniae. In vitro studies have 
shown that if time above MIC increases up to approxi-
mately 80% of the dose-interval, the antimicrobial effect 
increases which could be of clinical importance [22, 24]. 
The results reported here show that more extended drug 
Fig. 3 Total plasma concentration–time courses of benzylpenicillin in pigs after repeated intramuscular dosing of different formulations. 
Total plasma concentration–time courses of benzylpenicillin after repeated intramuscular dosing of different formulations of the drug in pigs 
experimentally inoculated with Actinobacillus pleuropneumoniae serotype 2. Each line represents an individual pig. Discontinuation of the 
concentration–time courses means that no samples were collected within one dose-interval. Plot a 30 mg/kg Ultrapen qd to twelve pigs for 3 days 
and to six of these for an additional 2 days. Plot b A single dose of 30 mg/kg Ethacilin followed by repeated administration of 30 mg/kg Ultrapen 
qd for 3 days starting at 12 h in six pigs. Plot c 30 mg/kg Ethacilin bid for 5 days to six pigs. Plot d an initial dose of 60 mg/kg Ultrapen followed 
by 30 mg/kg qd for 2 days starting at 24 h to six pigs. The horizontal lines denote the approximate total plasma concentration of benzylpenicillin 
necessary to exceed MIC of 500 µg/L for A. pleuropneumoniae, considering a protein binding of 45%
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exposure over a longer period of time is achieved for the 
oil suspension of benzylpenicillin, without any observed 
unwanted effects. This was nicely demonstrated when 
ETH 30  mg/kg bid was compared with UPA 30  mg/
kg qd (Fig.  3). However, all dosage regimens in Part III 
appeared to produce sufficient exposure to successfully 
treat an infection caused by bacteria with a MIC of ben-
zylpenicillin less than or equal to 500 µg/L. It should be 
observed that the total concentration should be twice the 
MIC for 50% of the dose-interval, considering that the 
plasma protein binding for benzylpenicillin in pigs is up 
to 45% [17, 18]. This free fraction is also consistent with 
what is reported in porcine serum for another penicillin 
than benzylpenicillin [25]. In contrast to dosage regimens 
studied in Part III, free plasma concentrations fell below 
500  µg/L within 12  h after administration of 20  mg/kg 
once daily (the approved dose). Consequently, at that 
dose there is a risk for therapeutic failure when infec-
tions are caused by bacteria with a benzylpenicillin MIC 
of 500 µg/L, e.g. A. pleuropneumoniae, of which a major-
ity of the wild type isolates have benzylpenicillin MICs of 
250 or 500 µg/L [9, 16]. Hence, the results from this study 
likely explain the poor therapeutic outcome of 20 mg/kg 
procaine benzylpenicillin to pigs experimentally infected 
with A. pleuropneumoniae [26–28].
The relatively few numbers of pigs used per dosage reg-
imen may be a limitation to this study, especially in the 
light of the high variability in plasma exposure. However, 
using as few animals as possible is well in line with the 
3R principle; replace, reduce, refine. A pharmacokinetic 
model would possibly been able to quantify the vari-
ability in experimental data. However, IV-data from two 
pigs suggest an additional terminal phase with longer 
half-life than what could be detected in the other pigs. 
Hence, the area under the curve and subsequently the 
plasma clearance and the bioavailability would be incor-
rectly estimated by the model. Since those are two out 
of three parameters that govern the plasma concentra-
tion at steady state, no modelling was performed in this 
study. Nevertheless, the results clearly indicate how dos-
age regimens to pigs can be adjusted in clinical practice 
to achieve successful therapy of bacteria with benzylpeni-
cillin MICs of 500 µg/L. Thus, by applying the informa-
tion from this study in clinical practice, optimized dosage 
regimens can be selected for improved treatment out-
comes. This is consistent with prudent use guidelines and 
will improve animal welfare and reduce the risk for emer-
gence of resistance, preserving the effect of antibiotics 
already on the market.
Conclusion
The approved IM dosage for ETH (20  mg/kg, qd) pro-
vided insufficient plasma benzylpenicillin exposure for 
therapy of infections caused by A. pleuropneumoniae or 
other bacteria with a wild type MIC of 500  µg/L. More 
frequent dosing (bid) or an increased dosage would 
improve exposure. However, the formulation with slower 
absorption, UPA, provided adequate exposure at the 
approved IM dosage (30 mg/kg, qd).
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